Brief: Hoth Therapeutics (Hoth) Reports Positive Ht-Va Crada Data Gdnf Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene And Activates Fat-Burning Pathways, Outperforming Semaglutide
13/04/2026 22:25
April 13 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS (HOTH) REPORTS POSITIVE HT-VA CRADA DATA: GDNF REPROGRAMS LIVER FAT METABOLISM, SHUTS DOWN FAT-CREATION GENE AND ACTIVATES FAT-BURNING PATHWAYS, OUTPERFORMING SEMAGLUTIDE HOTH THERAPEUTICS INC - GDNF SHOWS SIGNIFICANT SREBF1 REDUCTION AND PPARΑ INCREASE IN MAFLD AND OBESITY MODEL HOTH THERAPEUTICS INC - GDNF OUTPERFORMS SEMAGLUTIDE IN GENE MARKERS RELATED TO LIVER FAT REGULATION Source text: ID:nPnbN41hba Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology